331 related articles for article (PubMed ID: 36041544)
1. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
2. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
3. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
5. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?
Puigdevall L; Michiels C; Stewardson C; Dumoutier L
J Cell Mol Med; 2022 Apr; 26(7):1865-1875. PubMed ID: 35238133
[TBL] [Abstract][Full Text] [Related]
7. JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
Godoi MA; Camilli AC; Gonzales KGA; Costa VB; Papathanasiou E; Leite FRM; Guimarães-Stabili MR
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373437
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
Karati D; Mahadik KR; Trivedi P; Kumar D
Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
11. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
[TBL] [Abstract][Full Text] [Related]
12. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
13. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
15. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
16. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
17. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
19. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
Cai B; Cai JP; Luo YL; Chen C; Zhang S
Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
[TBL] [Abstract][Full Text] [Related]
20. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
